[Clinical utility of adjuvant TC regimen].
Department of Breast Oncology, NHO Shikoku Cancer Center.
Kenjiro
K
Aogi
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D000077143:Docetaxel; D005260:Female; D006801:Humans; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects
D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D043823:Taxoids; D000077143:Docetaxel; D003520:Cyclophosphamide